カテゴリー： GlobalData, 企業調査

Immunicum AB (IMMU)：製薬・医療：M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書（DATA904C8207）
◆英語タイトル：Immunicum AB (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8207
◆発行会社（リサーチ会社）：GlobalData
◆発行日：2018年10月
◆ページ数：64
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：スウェーデン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥34,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥69,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥103,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

 【レポートの概要】

Summary
Immunicum AB (Immunicum) is a biopharmaceutical company that focuses on the development of immuno-oncology therapies for the treatment of solid tumors. The company’s lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell carcinoma, renal cell carcinoma, and gastrointestinal stromal carcinoma; and for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. Its technology platform programs include COMBIG, SUBCUVAX, Ad5PTDf35 – Adenovirusvector and CD70, among others. Immunicum spans its expertise in the development of allogeneic and off-the-shelf cell-based therapies. The company works in partnership with various academia, biotech and pharmaceutical companies to develop and commercialize new therapeutics. Immunicum is headquartered in Gothenburg, Sweden.

Immunicum AB (IMMU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunicum AB, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 11
Partnerships 12
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Immunicum Enters into Research Agreement with Rutgers Cancer Institute 13
Equity Offering 14
Immunicum to Raise USD19.32 Million in Rights Offering of Shares 14
Immunicum Raises USD24.2 Million in Rights Offering of Shares 16
Immunicum Raises USD15.5 Million in Right Offering of Shares 18
Immunicum Raises USD6.8 Million in Rights Offering of Shares 20
Immunicum Raises USD8.66 Million in Private Placement of Shares 21
Immunicum Completes IPO 22
Immunicum Announces Private Placement Of Shares For US$1.3 Million 23
Immunicum AB – Key Competitors 24
Immunicum AB – Key Employees 25
Immunicum AB – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 17, 2018: Immunicum announce interim report April – June 2018 27
May 04, 2018: Immunicum Interim report January – March 2018 29
Feb 16, 2018: Immunicum Reports Net Loss Of TSEK18,826 In Fourth Quarter Of 2017 31
Nov 17, 2017: Immunicum Interim Report Q3-Corporate Update and Outlook 33
Aug 18, 2017: Immunicum: Interim Report Q2 – Corporate Update and Outlook 35
May 19, 2017: Immunicum: Quarterly Report January-March 2017 37
Feb 17, 2017: Immunicum: Year-End Report 2016 (July 2016 – December 2016) 39
Corporate Communications 42
Sep 17, 2018: Immunicum names Pawel Kalinski and Inge Marie Svane to scientific advisory board 42
Mar 14, 2018: The Nomination Committee of Immunicum proposes Michael Oredsson as new Chairman of the Board 43
Jan 31, 2018: Immunicum Appoints Michaela Gertz As CFO 44
Product News 45
09/28/2017: Immunicum Announces Completion of HCC Phase I/II Clinical Study –Topline Safety and Immune Response Data Support Continued Development of Ilixadencel in Liver Cancer 45
08/15/2017: Immunicum Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study 47
06/20/2017: Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s First Clinical Study in Metastatic Renal Cell Carcinoma 48
06/12/2017: Immunicum Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX 50
02/05/2018: Immunicum Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference 51
Product Approvals 52
Mar 20, 2018: Immunicum Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data 52
Clinical Trials 53
Apr 03, 2018: Immunicum Provides Update on Ilixadencel Clinical Development Program 53
Jan 08, 2018: Immunicum Announces Completion of Patient Recruitment for Phase II MERECA Trial 55
Nov 27, 2017: Immunicum Announces Positive Preliminary Results from Proof-of- Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors 56
Nov 10, 2017: Immunicum and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology 57
Nov 07, 2017: Immunicum Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting 58
Sep 21, 2017: Immunicum to Present Preclinical Data on Ilixadencel’s Mode of Action at the SITC Meeting in the US 59
Aug 17, 2017: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel 60
Aug 10, 2017: Immunicum Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel 61
Feb 14, 2017: Immunicum announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma 62
Other Significant Developments 63
Dec 04, 2017: Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Immunicum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Deals By Therapy Area, 2012 to YTD 2018 9
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 11
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Immunicum Enters into Research Agreement with Rutgers Cancer Institute 13
Immunicum to Raise USD19.32 Million in Rights Offering of Shares 14
Immunicum Raises USD24.2 Million in Rights Offering of Shares 16
Immunicum Raises USD15.5 Million in Right Offering of Shares 18
Immunicum Raises USD6.8 Million in Rights Offering of Shares 20
Immunicum Raises USD8.66 Million in Private Placement of Shares 21
Immunicum Completes IPO 22
Immunicum Announces Private Placement Of Shares For US$1.3 Million 23
Immunicum AB, Key Competitors 24
Immunicum AB, Key Employees 25
Immunicum AB, Other Locations 26

List of Figures
Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ Immunicum AB (IMMU)：製薬・医療：M&Aディール及び事業提携情報(Immunicum AB (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • Central Alabama Electric Cooperative Inc：企業の戦略的SWOT分析 Central Alabama Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A...
  • DeepOcean Group Holding BV：企業の戦略的SWOT分析 DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed...
  • Kajima Corp (1812)：企業の財務・戦略的SWOT分析 Kajima Corp (1812) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s...
  • Shanghai Pharmaceutical Co Ltd (601607)：医療機器：M&Aディール及び事業提携情報 Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic anti-infection, and antineoplastic drug and immunomodulator. It also offers pharmaceuticals for diseases and disorders of cardiovascular system, digestive and metabolism, neurological system, musculoskeletal system, and respiratory system. The company also provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. Shanghai Pharma also provides traditional Chinese medicines....
  • Tauron Polska Energia SA：企業の発電所・SWOT分析2018 Tauron Polska Energia SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized and detailed information about the power plants (assets). - Operational Metrics (capacity, generation, revenue, sales, number of consumers). - Business description - A detailed description of the company’s operations and business divisions. - Corporate strategy - GlobalData’s summarization of the company’s business strategy....
  • Kurabo Industries Ltd (3106)：企業の財務・戦略的SWOT分析 Kurabo Industries Ltd (3106) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy –...
  • Covalon Technologies Ltd (COV)：製品パイプライン分析 Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen matrix dressing, collagen matrix dressing with silver, wound contact layer, non-adherent foam dressing and superabsorbent dressing, among others. Its infection prevention products and perioperative care product includes self-adherent silicone dressing with absorbent pad, antimicrobial clear silicone adhesive dressing with chlorhexidine and silver and silicone foley catheter, among others. The company also develops and commercializes proprietary technologies in the areas of advanced wound...
  • GlaxoSmithKline Plc (GSK)-医療機器分野：企業M&A・提携分析 Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex,...
    • ◆H&Iグローバルリサーチのお客様（例）◆